Bayer has filed an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for marketing authorization of the oral androgen receptor inhibitor… read more.
Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation announced that Eli Lilly Japan received manufacturing and marketing authorization in Japan from the Japanese Ministry of Health, Labour… read more.
New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th American Society… read more.
30 December 2024-Orion Corporation and Marinus Pharmaceuticals, Inc. have decided to mutually terminate their European wide marketing and distribution agreement for ganaxolone. Marinus regains ganaxolone’s commercial rights in… read more.
Theramex, a global pharmaceutical company dedicated to women’s health, is pleased to announce that the European Commission (EC) has approved an extended indication for Yselty (linzagolix), an oral… read more.
NICE (UK): 1.1 Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have:… read more.
Medtronic plc announced new data for the Evolut Transcatheter Aortic Valve Replacement System (TAVR) at PCR London Valves 2024. This new clinical evidence brings further insights to global… read more.
Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K. announced that Ono has received a supplemental approval of Opdivo (generic name: nivolumab) Intravenous Infusion (“Opdivo”), an anti-PD-1 antibody, in… read more.
Checkpoint Therapeutics, Inc. announced that the FDA has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who… read more.
Roche announced that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presented at the 66th American Society of Hematology (ASH) Annual Meeting &… read more.
Novartis announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqal (ribociclib) that underscore the extended efficacy beyond the duration of treatment in… read more.
Neurocrine Biosciences, Inc. announced the FDA approved Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
